The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Randomized Trial of [131I] Metuximab in Treatment of Hepatocellular Carcinoma After Percutaneous Radiofrequency Ablation
Bian H1, Zheng JS1, Nan G1, Li R1, Chen C1, Hu CX1, Zhang Y1, Sun B1, Wang XL1, Cui SC1, Wu J1, Xu J1, Wei D1, Zhang X1, Liu H1, Yang W1, Ding Y1, Li J1, Chen ZN2. J Natl Cancer Inst. 2014 Sep 10;106(9). pii: dju239. doi: 10.1093/jnci/dju239. Print 2014 Aug.
Author information
1Cell Engineering Research Center and Department of Cell Biology, State Key Laboratory of Cancer Biology (HB, GN, YZ, XLW, JW, JX, DW, ZNC) and Department of Health Statistics (CC), Fourth Military Medical University, Xi'an, China; Oncology and Hepatobiliary Minimally Invasive Interventional Center, Beijing Youan Hospital, Capital Medical University, Beijing, China (JSZ, RL, CXH, BS, SCC); Radionuclide Diagnosis and Treatment Center, No. 401 Hospital of China Nuclear Industry, Beijing, China (XZ, HL); Tumor Minimally Invasive Therapy Division (WY, JL) and Department of Nuclear Medicine (YD), Hospital 307 of PLA, Beijing, China.
2Cell Engineering Research Center and Department of Cell Biology, State Key Laboratory of Cancer Biology (HB, GN, YZ, XLW, JW, JX, DW, ZNC) and Department of Health Statistics (CC), Fourth Military Medical University, Xi'an, China; Oncology and Hepatobiliary Minimally Invasive Interventional Center, Beijing Youan Hospital, Capital Medical University, Beijing, China (JSZ, RL, CXH, BS, SCC); Radionuclide Diagnosis and Treatment Center, No. 401 Hospital of China Nuclear Industry, Beijing, China (XZ, HL); Tumor Minimally Invasive Therapy Division (WY, JL) and Department of Nuclear Medicine (YD), Hospital 307 of PLA, Beijing, China. znchen@fmmu.edu.cn zhengjiasheng6@163.com.
Abstract
To assess the efficacy of combining radioimmunoconjugate [(131)I] metuximab with radiofrequency ablation (RFA) in hepatocellular carcinoma (HCC) treatment compared with RFA alone, a single-center randomized controlled trial was conducted on 127 patients with Barcelona Clinic Liver Cancer staging system (BCLC) classifications of 0-B stage. Patients received either RFA followed by [(131)I] metuximab (n = 62) or RFA alone (n = 65). The primary outcome was overall tumor recurrence. Statistical tests were two-sided. The one- and two-year recurrence rates in the combination group were 31.8% and 58.5%, whereas those in the RFA group were 56.3% and 70.9%, respectively. The median time to overall tumor recurrence was 17 months in the combination group and 10 months in the RFA group (P = .03). The RFA-[(131)I] metuximab treatment showed a greater antirecurrence benefit than RFA in the metuximab target (ie, CD147)-positive subpopulation (P = .007). [(131)I] metuximab may yield prevention of tumor recurrence after RFA.